Dipartimento Area Emergenza-Urgenza, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, Italy.
Department of Pathophysiology and Transplantation, University of Milan, Padiglione Litta, Milan, Italy.
Intern Emerg Med. 2024 Sep;19(6):1593-1604. doi: 10.1007/s11739-024-03641-4. Epub 2024 Jul 23.
During COVID-19 pandemic, vaccination has been strongly recommended and advocated to prevent COVID-19 infection and adverse outcomes, particularly among at-risk populations. The vaccination against SARS-CoV-2 (COVAC) occurred at off-site locations capable of accommodating large crowds, distinct from the hospital setting, where a team of intensivists, emergency physicians, and nurses, ensuring prompt medical attention (medical occurrences, MO) in cases of adverse event following immunization. Our aims were to estimate the incidence of MO, and to assess its association with demographics, and vaccine characteristics. Our retrospective cohort study included all subject aged 12 years and older who received vaccinations at two large out-of-hospital vaccination hubs (Fiera Milano City, Palazzo delle Scintille), between April 12th and August 31st, 2021. Nine hundred and ninety-five thousand and twenty-eight vaccinations were administrated. MOs incidence rate was 278/100,000 doses (95% confidence interval (CI) 268-289). Most MOs were mild (86.27%) and mainly observed in subjects who received the Comirnaty vaccine; 92 MOs (3.32%) were severe and mostly occurred in recipients of the Vaxzeria vaccine. The incidence rate for hospital transfers following vaccination was 4.7/100,000 doses (95% CI 3.5-6.2) and any level of anaphylaxis occurred in 0.4 cases per 100,000 administrated doses (95% CI 0.3.-0.7). Sex, age, type of vaccine and first dose were associated with incidence of MO. Our results showed a low incidence rate in MOs after COVAC, mainly mild and support the feasibility, effectiveness and safety of vaccinations administered in hubs with a dedicated SEU located outside of the hospital setting.
在 COVID-19 大流行期间,强烈建议和提倡接种疫苗以预防 COVID-19 感染和不良后果,特别是在高危人群中。针对 SARS-CoV-2(COVAC)的疫苗接种是在能够容纳大量人群的场外地点进行的,与医院环境不同,那里有一组重症监护医生、急诊医生和护士,以确保在接种后出现不良事件时能得到及时的医疗关注(医疗事件,MO)。我们的目的是估计 MO 的发生率,并评估其与人口统计学和疫苗特征的关联。我们的回顾性队列研究包括 2021 年 4 月 12 日至 8 月 31 日期间在两个大型场外疫苗接种中心(米兰会展城,Palazzo delle Scintille)接受疫苗接种的所有年龄在 12 岁及以上的受试者。共接种了 995 万 2800 剂疫苗。MO 发生率为 278/100,000 剂(95%置信区间(CI)268-289)。大多数 MO 是轻度的(86.27%),主要发生在接受 Comirnaty 疫苗的受试者中;92 例 MO(3.32%)为重度,主要发生在接受 Vaxzeria 疫苗的受试者中。接种疫苗后住院转移的发生率为 4.7/100,000 剂(95%CI 3.5-6.2),每 100,000 剂中发生任何程度过敏反应的比例为 0.4 例(95%CI 0.3.-0.7)。性别、年龄、疫苗类型和首剂与 MO 发生率相关。我们的结果显示 COVAC 后 MO 发生率较低,主要为轻度,支持在远离医院环境的专门 SEU 场外地点接种疫苗的可行性、有效性和安全性。